Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

Treg therapy ensures success of hematopoietic stem cell transplantation, without triggering GVHD

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies to kick off in Lund, Sweden

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies to kick off in Lund, Sweden

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Elsevier acquires Cancer Information Group's oncology journals portfolio

Elsevier acquires Cancer Information Group's oncology journals portfolio

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Antibiotic may help in development of new anti-cancer agents: Researchers

Antibiotic may help in development of new anti-cancer agents: Researchers

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Scientist examines tungsten contamination in drinking water

Scientist examines tungsten contamination in drinking water

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Prototype drug halts GVHD in mouse models of bone marrow transplantation

API2-MALT1 fusion protein appears to trigger cancer

API2-MALT1 fusion protein appears to trigger cancer

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

American Red Cross urges all eligible donors to donate blood

American Red Cross urges all eligible donors to donate blood

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Researchers reveal how genetic mutation contributes to cancer development

Researchers reveal how genetic mutation contributes to cancer development

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.